Infringement action filed 30 Dec 2021 in the United States District Court for the District of New Jersey and closed 17 Apr 2023, with 14 patents asserted. Recorded basis of termination: case settled.
Low-dose doxepin formulations and methods of making and using the same · Methods of improving the pharmacokinetics of doxepin · Methods of using low-dose doxepin for the improvement of sleep
Source: Patsnap Litigation Data. Case 1:21-cv-20765, United States District Court for the District of New Jersey.Open this record in Eureka
Patsnap Eureka
Check this patent against your own product
Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.
Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).
The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep.
The docket lists 14 asserted patents. Full bibliographic detail, drawings and prosecution history for the remaining 12 asserted patents are one query away in Eureka.
Source: case record + Patsnap company data. Attorney names appear as recorded in the docket.Compare both portfolios
Outcome
Basis of termination
From the record · verbatim
"It having been reported to the Court that the above−captioned action has been settled, IT IS on this 17th day of April, 2023, ORDERED that this action and any pending motions are hereby administratively terminated; and it is further ORDERED that this shall not constitute a dismissal Order under the Federal Rules of Civil Procedure; and it is further ORDERED that within 60 days after entry of this Order (or such additional period authorized by the Court), the parties shall file all papers necessary to dismiss this action under the Federal Rules of Civil Procedure or, if settlement cannot be consummated, request that the action be reopened; and it is further ORDERED that, absent receipt from the parties of dismissal papers or a request to reopen the action within the 60−day period, the Court shall dismiss this action, without further notice, with prejudice and without costs."
Case 1:21-cv-20765 · D.N.J. · closed 17 April 2023
Source: case record, verbatim. The quoted paragraph is the basis-of-termination text as filed.
Related cases
Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.
1:21-cv-20765 is a patent infringement action brought by Currax Pharmaceuticals, LLC against Aurolife Pharma, LLC, filed on 30 Dec 2021 in the United States District Court for the District of New Jersey. The case closed on 17 April 2023.
Which patents were asserted in 1:21-cv-20765?
US9486437B2 (“Methods of using low-dose doxepin for the improvement of sleep”), assigned to CURRAX PHARMACEUTICALS LLC, currently active; US9907780B2 (“Low-dose doxepin formulations and methods of making and using the same”), assigned to CURRAX PHARMACEUTICALS LLC, currently active; US10653662B2 (“Methods of using low-dose doxepin for the improvement of sleep”), assigned to CURRAX PHARMACEUTICALS LLC; US9861607B2 (“Methods of using low-dose doxepin for the improvement of sleep”), assigned to CURRAX PHARMACEUTICALS LLC; US8513299B2 (“Methods of using low-dose doxepin for the improvement of sleep”), assigned to CURRAX PHARMACEUTICALS LLC|PROCOM ONE, INC.|MIDCAP FUNDING IV, LLC; US10548871B2 (“Low-dose doxepin formulations and methods of making and using the same”), assigned to CURRAX PHARMACEUTICALS LLC; US9532971B2 (“Low-dose doxepin formulations and methods of making and using the same”), assigned to CURRAX PHARMACEUTICALS LLC; US7915307B2 (“Methods of improving the pharmacokinetics of doxepin”), assigned to CURRAX PHARMACEUTICALS LLC|MIDCAP FUNDING IV, LLC; US11110074B2 (“Methods of improving the pharmacokinetics of doxepin”), assigned to CURRAX PHARMACEUTICALS LLC; US9572814B2 (“Methods of improving the pharmacokinetics of doxepin”), assigned to MIDCAP FUNDING IV, LLC|CURRAX PHARMACEUTICALS LLC; US9107898B2 (“Methods of using low-dose doxepin for the improvement of sleep”), assigned to CURRAX PHARMACEUTICALS LLC|MIDCAP FUNDING IV, LLC; US11096920B2 (“Low-dose doxepin formulations and methods of making and using the same”), assigned to CURRAX PHARMACEUTICALS LLC; US10238620B2 (“Methods of using low-dose doxepin for the improvement of sleep”), assigned to CURRAX PHARMACEUTICALS LLC; US10653660B2 (“Methods of improving the pharmacokinetics of doxepin”), assigned to CURRAX PHARMACEUTICALS LLC. The record also lists Low-dose doxepin formulations and methods of making and using the same, Methods of improving the pharmacokinetics of doxepin and Methods of using low-dose doxepin for the improvement of sleep.
How was case 1:21-cv-20765 terminated?
The recorded basis of termination is case settled. The termination text reads: "It having been reported to the Court that the above−captioned action has been settled, IT IS on this 17th day of April, 2023, ORDERED that this action and any pending motions are hereby administratively terminated; and it is further ORDERED that this shall not constitute a dismissal Order under the Federal Rules of Civil Procedure; and it is further ORDERED that within 60 days after entry of this Order (or such additional period authorized by the Court), the parties shall file all papers necessary to dismiss this action under the Federal Rules of Civil Procedure or, if settlement cannot b
What does dismissal with prejudice mean?
A dismissal with prejudice permanently ends the claims that were filed, so the same claims cannot be brought again against that defendant. It is the usual form when the parties have settled.
How long did case 1:21-cv-20765 take?
473 calendar days, from filing on 30 Dec 2021 to closure on 17 April 2023.
Who were the attorneys and the judge in 1:21-cv-20765?
Chief Judge Christine P. O presided. Jessica K. Formichella and Katelyn O. are recorded as counsel for plaintiff Currax Pharmaceuticals. R. Touhey Myer appears for defendant Aurolife Pharma.
Answers reproduce fields from the case record for 1:21-cv-20765 and do not constitute legal advice.Ask your own question
Disclaimer. This page reproduces publicly available court docket data for case 1:21-cv-20765 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.
